Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
Standalone hospitals are increasingly rare in today's healthcare landscape. Health systems must manage a much broader portfolio of non-acute sites than ever before, with care settings ranging from physician offices and ambulatory service centers to urgent and long-term care.
Mylan faced a firestorm of criticism last year for the high price of EpiPens, which increased nearly 400 percent since 2004. Despite immense public scrutiny, a CMS rebate scandal and several federal hearings all spurred by the product's price, a…
The Food and Drug Administration has approved 21 new drugs so far in 2017, with several regulatory decisions set to be made this month, according to Zacks Investment Research.
Companies with supply chain leaders in the C-suite experience stronger operational performance than those where supply chain leaders take on a middle management role, according to Geodis' 2017 Supply Chain Worldwide Survey.
Knoxville-based University of Tennessee's supply chain program partners with various industry members to provide students with valuable real world experience, reports Knoxville News Sentinel.
After mergers or acquisitions, health systems typically look to move select hospital functions into a corporate organization, including those in the supply chain. While this strategy may make good business sense, local hospital CEOs are often reluctant to move functions…
Pfizer on June 1 increased the U.S. list prices for nearly 100 drugs in its second price hike of the year, reports Financial Times.
Scott Anderson, CEO and chairman of Saint Paul, Minn.-based Patterson Companies, stepped down Thursday from the role he held since 2010, according to the Minneapolis Star-Tribune.
Here are seven articles published by Becker's Hospital Review this week, highlighting a critique on the lack of diversity in the supply chain industry and a look into Walmart's unique package delivery pilot program, among other topics.
Annual global spending on cancer drugs peaked at $113 billion in 2016, according to a 2017 global oncology trends report from the QuintilesIMS Institute.